Dose Finding Study in COPD

1. Patients must have relatively stable, moderate to severe airway obstruction with an
FEV1 >=30% and <= 60% of predicted normal and FEV1 <=70% of FVC at the baseline PFTs
at Visit 1 (at both timepoints).

2. All patients must have an increase in FEV1 of at least 12% from baseline (th e -10
minute measurement) 45 min after inhalation of 80 ?g Atrovent MDI.

3. Male or female patients 40 years of age or older.

4. Smoker or ex-smoker with a history of more than 10 pack years.

1. Patients with any other significant disease will be excluded. 2. Patients with a history
of asthma or allergic rhinitis will be excluded.